Colorectal cancer's lethality lies less in the primary tumor than in its capacity to spread — and metastasis remains one of oncology's hardest problems. A new molecular target that sits at the junction of multiple cancer-driving pathways could represent a meaningful step toward interrupting that spread before it becomes irreversible.
Research published in Acta Pharmacologica Sinica identifies JOSD2, a deubiquitinase enzyme, as a critical stabilizer of β-catenin in colorectal cancer cells. Deubiquitinases remove the molecular tags that normally mark proteins for proteasomal destruction, and JOSD2 appears to perform this protective function for β-catenin — a protein central to the Wnt signaling cascade and a well-established driver of cancer invasiveness. The study demonstrates that targeting JOSD2 accelerates β-catenin degradation by disrupting the RAS/ERK/β-catenin signaling axis, thereby suppressing metastatic behavior in colorectal cancer models. The mechanistic link places JOSD2 upstream of oncogenic RAS and ERK kinase activity, suggesting the enzyme coordinates signals from multiple pro-metastatic routes simultaneously.
Deubiquitinases as a drug target class have attracted intensifying interest over the past decade, yet the field has struggled to translate mechanistic discoveries into viable therapeutics — the enzymes are numerous, structurally similar, and context-dependent in their substrates. JOSD2's apparent role as a node connecting RAS, ERK, and Wnt signaling is what distinguishes this finding from incremental pathway studies: targeting a single enzyme could theoretically disrupt crosstalk that individual pathway inhibitors cannot. That said, this work appears to be primarily preclinical, likely relying on cell-line and animal models, which means substantial translational distance remains. RAS-pathway inhibition has a complex history of resistance and off-target toxicity in colorectal cancer, and whether JOSD2 inhibition avoids those pitfalls is unknown. This is an incremental but directionally interesting finding that adds JOSD2 to a shortlist of deubiquitinases warranting closer drug-development attention.